Quoin Pharmaceuticals, Ltd. (QNRX) is a publicly traded company in the Unknown sector. Across all available filings, 4 corporate insiders have executed 15 transactions totaling $209.9K, demonstrating a bullish sentiment with $209.5K in net insider flow. The most recent transaction on Oct 14, 2025 involved a purchase of 15,152 shares valued at $128.6K.
No significant insider buying has been recorded for QNRX in the recent period.
No significant insider selling has been recorded for QNRX in the recent period.
Based on recent SEC filings, insider sentiment for QNRX is bullish with an Insider Alignment Score of 100/100 and a net flow of $209.5K. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Quoin Pharmaceuticals, Ltd. (QNRX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 4 insiders are actively trading QNRX stock, having executed 15 transactions in the past 90 days. The most active insider is Dennis Langer (Executive), who has made 2 transactions totaling $128.9K.
Get notified when executives and directors at QNRX file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Oct 14, 2025 | Langer Dennis | Executive | Purchase | 15,152 | $8.49 | $128.6K | |
| Sep 10, 2024 | Dunn Gordon | Executive | Purchase | 10,000 | $0.71 | $7.1K | |
| Sep 10, 2024 | Dunn Gordon | Executive | Purchase | 10,000 | $0.91 | $9.1K | |
| Sep 9, 2024 | Dunn Gordon | Executive | Purchase | 856 | $0.80 | $685 | |
| Sep 9, 2024 | Dunn Gordon | Executive | Purchase | 4,000 | $0.78 | $3.1K | |
| Sep 9, 2024 | Dunn Gordon | Executive | Purchase | 4,000 | $0.80 | $3.2K | |
| Sep 4, 2024 | Myers Michael | Executive | Purchase | 8,200 | $0.75 | $6.2K | |
| Sep 4, 2024 | Myers Michael | Executive | Purchase | 23,572 | $0.80 | $18.9K | |
| Sep 4, 2024 | Myers Michael | Executive | Purchase | 5,322 | $0.66 | $3.5K | |
| Sep 4, 2024 | P. Carter Denise | Executive | Purchase | 22,988 | $0.80 | $18.4K | |
| Sep 4, 2024 | P. Carter Denise | Executive | Purchase | 8,825 | $0.75 | $6.6K | |
| Sep 3, 2024 | Myers Michael | Executive | Purchase | 800 | $0.62 | $496 | |
| Sep 3, 2024 | P. Carter Denise | Executive | Purchase | 1,822 | $0.63 | $1.1K | |
| Sep 3, 2024 | P. Carter Denise | Executive | Purchase | 4,100 | $0.66 | $2.7K | |
| Jun 7, 2024 | Langer Dennis | Executive | Sale | 297 | $0.73 | $217 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 14 | $209.7K | 99.9% |
Sale(S) | 1 | $217 | 0.1% |
Insiders at Quoin Pharmaceuticals, Ltd. are accumulating shares at an accelerated pace. With 4 insiders making 15 transactions totaling $209.7K in purchases versus $217 in sales, the net buying activity of $209.5K signals strong executive confidence. Dennis Langer (Executive) leads the buying activity with $128.9K in transactions across all time.